All News
Differences in presentation of PsA in men and women. Crucial to incorporate this into your diagnostic formulation @lihi_eder @RheumNow #RNL2024 https://t.co/uvnU1ujCX7
Richard Conway RichardPAConway ( View Tweet)
Key take home points from @_AprilArmstrong on psoriatic disease @RheumNow #RNL2024 https://t.co/Svx9gNKBuR
Richard Conway RichardPAConway ( View Tweet)
Men with PsA have more severe psoriasis, axial disease, high CRP, erosive disease compared to women, but women tend to have more pain. Delay to diagnosis in female patients are likely related to these differences- Dr. Eder #RNL2024 @rheumnow https://t.co/S9dzANITfH
TheDaoIndex KDAO2011 ( View Tweet)
Nice summary of data as to why IL-17 or IL-23 are generally favoured by dermatology for psoriasis @_AprilArmstrong @RheumNow #RNL2024 https://t.co/qfAn2AHilX
Richard Conway RichardPAConway ( View Tweet)
Key takeaways when choosing therapies anti-TNFs, IL-17i, IL-23i, JAKs and TYK-2, in psoriasis. Think of skin, joint and spine involvement, April Armstrong #RNL2024 @RheumNow https://t.co/nUMmQk4xZq
Links:
Dr. Antoni Chan synovialjoints ( View Tweet)
#RNL2024 @RheumNow
@_AprilArmstrong: Deucravacitinib v Apremilast
Deucra: TYK2 inhibitor, approved for PsO (not yet PsA)
Superior to apremilast for skin disease (sPGA) https://t.co/NRnsm4cOum
Eric Dein ericdeinmd ( View Tweet)
Dr. A. Armstrong's Key Takeaways for PsO.
TNFi - great in PsA and pregnancy
IL-17i - robust PsO efficacy and in PsA
IL-23i - robust in PsO, fewer injections, and efficacious in PsA.
#RNL2024 @RheumNow @_AprilArmstrong https://t.co/j8LaOGITuf
Dr. Rachel Tate uptoTate ( View Tweet)
How are dermatology colleagues may frame our treatment options @_AprilArmstrong . This is helpful to consider in light of shared care discussions. The lack of love for JAKi in particular. @RheumNow #RNL2024 https://t.co/pv5EFXsXjI
Richard Conway RichardPAConway ( View Tweet)
#RNL2024 @RheumNow
@_AprilArmstrong
Bimekizumab: IL-17A and IL-17F dual efficacy, unlike the prior IL-17i drugs
- Fast onset
- High efficacy with 2/3 PASI 100 by wk 16 (BE READY) https://t.co/cKh7j4KBs9
Eric Dein ericdeinmd ( View Tweet)
In a patient with purely skin limited plaque psoriasis without systemic involvement, what would you choose for treatment? The rheum audience poll at #RNL2024 is all over the place in their choice! Dr. Armstrong lectures on how derms think about #psoriasis @rheumnow https://t.co/4YxaJPlpa5
TheDaoIndex KDAO2011 ( View Tweet)
Dr. April Armstrong shares a beautiful picture around pathophysiology in PsO/PsA, as demonstrated in a non-joint graphic below. "Consider the domains when choosing biologics." #RNL2024 @RheumNow https://t.co/4AtbEhysyA
Dr. Rachel Tate uptoTate ( View Tweet)
Derms are thinking like rheums now!
Dr. April Armstrong noted most derms digging below the surface to assess pts with psoriasis for systemic diseases to help them to choose systemic treatments. @rheumnow #RNL2024 https://t.co/7HTmiA6m4L
TheDaoIndex KDAO2011 ( View Tweet)
EULAR guidelines and GRAPPA guidelines are moving closer to each other in treatment approaches - @AlexisOgdie @rheumnow #RNL2024 https://t.co/wtp57s28Bz
TheDaoIndex KDAO2011 ( View Tweet)
EULAR 2019 PsA treatment guidelines, as detailed in 2023 presented by @AlexisOgdie
We are starting to see EULAR and GRAPPA guidelines complimenting each other with the caveat that EULAR tends to focus on oligo vs polyarticular, vs peripheral arthritis terminology in GRAPPA… https://t.co/K8gtI7Makm https://t.co/iK5x8hlIda
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Effects of obesity and weight loss in PsA. Very significant benefit, OR of MDA 6.67 for 10%+ weight loss @AlexisOgdie @RheumNow #RNL2024 https://t.co/130KAucPl7
Richard Conway RichardPAConway ( View Tweet)
GRAPPA recommendations 2021
Guide therapy by the active domains, filter by co-morbidities
@AlexisOgdie @RheumNow
#RNL2024 https://t.co/C1RQAM8DrI
Eric Dein ericdeinmd ( View Tweet)
Dr. @AlexisOgdie reviews the updated GRAPPA guideline and changes since 2015. #RNL2024 @RheumNow https://t.co/N2HAmlLj83
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
How to define "severe" disease? Erosions, multi-site involvement, affecting ADLs/QoL - @AlexisOgdie @rheumnow #RNL2024 https://t.co/gc8bSeSTyJ
TheDaoIndex KDAO2011 ( View Tweet)
2018 ACR/National Psoarasis Foundation Guidelines for Treatment of PsA
- Created helpful definitions of Severe PsA and Severe PsO
#RNL2024 @RheumNow @AlexisOgdie https://t.co/kH4UzlEWxA
Eric Dein ericdeinmd ( View Tweet)
Evolution of treatment landscape in PsA by @AlexisOgdie @RheumNow #RNL2024 https://t.co/ut1e5Z2CjK
Richard Conway RichardPAConway ( View Tweet)
